试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-12
[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers
编号:NCT03539731登记状态:提前终止企业 / 申办者:Guido A. Davidzon, MD, SM
药物 / 成分:Fluorine F 18 DASA-23、Positron Emission Tomography
登记的停止原因(原文):study did not meet its objectives due to difficulties in enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-12
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
编号:NCT03669640登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:RO6889450、Placebo
登记的停止原因(原文):This study was discontinued due to an interim analysis which indicated that ralmitaront was unlikely to meet its primary endpoint.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-12
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
编号:NCT04419558登记状态:提前终止企业 / 申办者:Kyntra Bio
药物 / 成分:Pamrevlumab、Placebo
登记的停止原因(原文):Sponsor Decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-09
Pazopanib Maintenance Phase II
编号:NCT02207309登记状态:提前终止企业 / 申办者:Ludwig-Maximilians - University of Munich
药物 / 成分:Pazopanib、Placebo (for Pazopanib)
登记的停止原因(原文):poor recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-09
Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms
编号:NCT02846883登记状态:提前终止企业 / 申办者:VA Office of Research and Development
药物 / 成分:1 million MSCs/kg、3 million MSCs/kg、Placebo
登记的停止原因(原文):Early Termination as required by VA DSMB due to slow enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-09
SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)
编号:NCT03050554登记状态:提前终止企业 / 申办者:Andrew Sharabi
药物 / 成分:Avelumab、SBRT
登记的停止原因(原文):Funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-09
A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
编号:NCT03355066登记状态:提前终止企业 / 申办者:Biosplice Therapeutics, Inc.
药物 / 成分:SM08502
登记的停止原因(原文):Study was terminated due business reasons by Sponsor.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-09
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
编号:NCT03387085登记状态:提前终止企业 / 申办者:ImmunityBio, Inc.
药物 / 成分:Aldoxorubicin HCl、N-803、ETBX-011、ETBX-051
登记的停止原因(原文):Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-09
Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
编号:NCT03672292登记状态:提前终止企业 / 申办者:Scynexis, Inc.
药物 / 成分:SCY-078、Voriconazole、Oral Placebo Tablets
登记的停止原因(原文):Enrollment took longer than anticipated (slow enrollment during COVID).
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-09
A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
编号:NCT03841448登记状态:提前终止企业 / 申办者:Alnylam Pharmaceuticals
药物 / 成分:Placebo、Cemdisiran
登记的停止原因(原文):Study was terminated early having identified clinically meaningful magnitude of proteinuria reduction due to cemdisiran (study goal). Participants completed DBT period\&were in OLE period. Sponsor had no concerns with safety\&integrity of participants.
查看官方原始记录 ↗